Recurrent Fallopian Tube Undifferentiated Carcinoma
3 clinical trials · Condition
◉ Watch Recurrent Fallopian Tube Undifferentiated Carcinoma
| Record | Firm | Date |
|---|---|---|
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NCT04739800) | National Cancer Institute (NCI) | 2021-06-10 |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02839707) | National Cancer Institute (NCI) | 2017-06-23 |
Track Recurrent Fallopian Tube Undifferentiated Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.